Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.

by Farshid Dayyani, Nila U Parikh, Andreas S Varkaris, Jian H Song, Shhyam Moorthy, Tanushree Chatterji, Sankar N Maity, Adam R Wolfe, Joan M Carboni, Marco M Gottardis, Christopher J Logothetis, Gary E Gallick
Published 2012-01-01